All In Biotech

NDA 202231 · Fresenius Kabi USA

Levothyroxine Sodium

Levothyroxine Sodium · Intravenous

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Jun 24, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

216

36 Phase 3, 17 recruiting

FAERS reports

101,616

70,416 serious, 8,379 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levothyroxine Sodium for Injection, should not be used for the treatment of obesity or for weight loss. ( 5.3 ) Larger doses may produce serious or even life threatening manifestations of toxicity. ( 6 ) WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levothyroxine Sodium for Injection, should not be used for the treatment of obesity or for weight loss. ( 5.3 ) Larger doses may produce serious or even life threatening manifestations of toxicity. ( 6 )

What it is approved for

From the label in effect Nov 2, 2026.

Levothyroxine Sodium for Injection is indicated for the treatment of myxedema coma. Important Limitations of Use: The relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established. Caution should be used when switching patients from oral levothyroxine products to Levothyroxine Sodium for Injection as accurate dosing conversion has not been studied. Levothyroxine Sodium is an L-thyroxine product. Levothyroxine (T 4 ) Sodium for Injection is indicated for the treatment of myxedema coma. ( 1 ) Important Limitations of Use: The relative bioavailability of this drug has not been established. Use caution when converting patients from oral to intravenous levothyroxine. ( 1 )

Mechanism: Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T 3 , the majority of which (approximately 80%) is derived from T 4 by deiodination in peripheral tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • LEVOTHYROXINE SODIUM · LEVOTHYROXINE SODIUM 200MCG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • LEVOTHYROXINE SODIUM · LEVOTHYROXINE SODIUM 500MCG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • LEVOTHYROXINE SODIUM · LEVOTHYROXINE SODIUM 100MCG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Levothyroxine" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue8,321
  • nausea7,290
  • diarrhoea6,612
  • headache6,428
  • dyspnoea6,344
  • drug ineffective5,446
  • pain5,349
  • dizziness5,097
  • vomiting4,552
  • asthenia4,372
  • off label use4,143
  • fall4,135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,043
20052,018
20062,180
20072,759
20084,015
20093,823
20104,305
20116,146
20126,819
20131,402
20141,713
20152,374
20163,138
20173,608
20184,138
20194,005
20205,441
20215,804
20227,390
20236,974
20247,345
20258,275
20265,900

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Levothyroxine Sodium* (Levothyroxine Sodium)

2024 spending

$464M

Beneficiaries

9,003,268

43,253,940 claims

Per beneficiary

$52

$0.17 per unit

View as table
YearSpending
2020$737,828,765
2021$722,461,732
2022$679,474,131
2023$653,580,460
2024$464,220,465

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 611 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.